Damora Therapeutics Inc (DMRA)

Currency in USD
29.420
-0.020(-0.07%)
Closed·
29.4200.000(0.00%)
·
Earnings results expected in 8 days
DMRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.40030.440
52 wk Range
2.45038.325
Key Statistics
Prev. Close
29.44
Open
29.53
Day's Range
28.4-30.44
52 wk Range
2.45-38.325
Volume
290.18K
Average Vol. (3m)
584.33K
1-Year Change
680.3714%
Book Value / Share
6.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DMRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
44.111
Upside
+49.94%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Damora Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 44.111
(+49.94% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy45.00+52.96%-MaintainJul 27, 2026
Jefferies
Buy50.00+69.95%-New CoverageJul 27, 2026
H.C. Wainwright
Buy45.00+52.96%-MaintainJul 21, 2026
H.C. Wainwright
Buy45.00+52.96%-New CoverageJun 11, 2026
TD Cowen
Buy---New CoverageJun 08, 2026

Earnings

Latest Release
May 12, 2026
EPS / Forecast
-0.62 / -0.32
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DMRA Income Statement

Compare DMRA to Peers and Sector

Metrics to compare
DMRA
Peers
Sector
Relationship
P/E Ratio
−7.7x−3.8x−0.4x
PEG Ratio
0.130.000.00
Price / Book
4.8x2.0x2.6x
Price / LTM Sales
-1.1x2.9x
Upside (Analyst Target)
52.9%242.9%56.8%
Fair Value Upside
Unlock21.7%8.9%Unlock

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.54M18.74%339.59M
Other Institutional Investors
61.82M81.26%1.82B
Public Companies & Retail Investors
0.000.00%0.00
Total
73.35M100.00%2.16B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC14.70%9,045,481266,299
Fairmount Funds Management LLC14.16%8,713,000256,511

People Also Watch

0.296
NXXT
-4.26%
24.04
NRIX
+2.60%
55.620
ASTS
-4.58%
4.5300
MNTS
-5.43%

FAQ

What Is the Damora Therapeutics (DMRA) Stock Price Today?

The Damora Therapeutics stock price today is 29.420 USD.

What Stock Exchange Does Damora Therapeutics Trade On?

Damora Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Damora Therapeutics?

The stock symbol for Damora Therapeutics is "DMRA."

What Is the Damora Therapeutics Market Cap?

As of today, Damora Therapeutics market cap is 1.820B USD.

What Is Damora Therapeutics's Earnings Per Share (TTM)?

The Damora Therapeutics EPS (TTM) is -24.470.

When Is the Next Damora Therapeutics Earnings Date?

Damora Therapeutics will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is DMRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Damora Therapeutics Stock Split?

Damora Therapeutics has split 1 times.

How Many Employees Does Damora Therapeutics Have?

Damora Therapeutics has 7 employees.

What is the current trading status of Damora Therapeutics (DMRA)?

As of Jul 28, 2026, Damora Therapeutics (DMRA) is trading at a price of 29.420 USD, with a previous close of 29.440 USD. The stock has fluctuated within a day range of 28.400 USD to 30.440 USD, while its 52-week range spans from 2.450 USD to 38.325 USD.

What Is Damora Therapeutics (DMRA) Price Target According to Analysts?

The average 12-month price target for Damora Therapeutics is 44.111 USD, with a high estimate of 51 USD and a low estimate of 35 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +49.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.